pplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes pmc-license-ref CC BY-NC-ND issue-copyright-statement © Springer-Verlag GmbH Germany, part of Springer Nature 2026 Background There is an overall trend of increased application of radioligand therapy (RLT) to treat prostate cancer [ 1 – 3 ], one of the most common malignancies in men worldwide [ 4 ].
← all excerpts
Dosimetry of [<sup>177</sup>Lu]Lu-PSMA therapy in a hemodialysis patient: a case study.
1
—
—